top of page

EC approves eribulin for the treatment of advanced liposarcoma

The European Commission (EC) has approved a variation to the terms of the Marketing Authorisation (MA) of Eisai’s eribulin for the treatment of adult patients with unresectable liposarcomas.

Eribulin is approved for those patients who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page